home.social

#medicalpharmaceuticals — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #medicalpharmaceuticals, aggregated by home.social.

  1. Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada

    TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…
    #NewsBeep #News #Healthcare #ApotexInc. #CA #Canada #Health #HealthCare&Hospitals #MedicalPharmaceuticals #NewProducts&Services #pharmaceuticals
    newsbeep.com/ca/670633/

  2. Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada

    TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…
    #NewsBeep #News #Healthcare #ApotexInc. #Health #HealthCare&Hospitals #healthcare #MedicalPharmaceuticals #NewProducts&Services #Pharmaceuticals #UK #UnitedKingdom
    newsbeep.com/uk/584941/

  3. Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development

    MONMOUTH JUNCTION, N.J., May 13, 2026 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”), a…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #ClinicalTrials&MedicalDiscoveries #CreatvMicroTech #Health #HealthCare&Hospitals #Inc. #medicalequipment #MedicalPharmaceuticals #Pharmaceuticals
    newsbeep.com/us/641021/

  4. Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development

    MONMOUTH JUNCTION, N.J., May 13, 2026 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”), a…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #ClinicalTrials&MedicalDiscoveries #CreatvMicroTech #Health #HealthCare&Hospitals #Inc. #medicalequipment #MedicalPharmaceuticals #Pharmaceuticals
    newsbeep.com/us/641021/

  5. Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera

    Ajax’s lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with…
    #NewsBeep #News #Healthcare #acquisitions #AU #Australia #EliLillyandCompany #Health #HealthCare&Hospitals #MedicalPharmaceuticals #MergersandTakeovers #Pharmaceuticals
    newsbeep.com/au/644881/

  6. MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements

    While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipelin…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Markets #biotechnology #Business #DelveInsightBusinessResearch #HealthCare&Hospitals #LLP #Marketresearchreports #MedicalPharmaceuticals #Pharmaceuticals
    newsbeep.com/us/10078/